Erratum to: Should ultrasound assessment of the endometrium be necessary in patients treated with Tamoxifen?

Open Access Editorial

Erratum to: Should ultrasound assessment of the endometrium be necessary in patients treated with Tamoxifen?

Georgios Iatrakis^1,, Stefanos Zervoudis^1,2, Angeliki Sarella¹, Panagiotis Tsikouras³, Minas Paschopoulos⁵, Myrsini Balafouta¹, Panagiotis Peitsidis ⁴^,*

¹University of West Attica, Athens, Greece

²Rea Hospital, Athens, Greece

³University Hospital of Alexandroupolis, Greece

⁴Helena Venizelou Hospital Athens, Greece

⁵University of Ioannina, Greece

*Corresponding author: Dr. Panagiotis Peitsidis PhD Msc, Obstetrician Gynecologist, Helena Venizelou Hospital Athens, Greece

Email: peitsidiobgyn@gmail.com

Download PDF

Published: 11 March 2024; https://doi.org/10.61873/FVLX2571

The Original Article was published on 22 February 2024

Abstract

Due to an unfortunate oversight of the corresponding author, Anastasia Bothou was included as an author of the editorial without her consent and knowledge. The citation of the editorial has now been amended as follows: Iatrakis G., Zervoudis S., Sarella A., Tsikouras P., Paschopoulos M., Balafouta M., Peitsidis P. Should ultrasound assessment of the endometrium be necessary in patients treated with Tamoxifen? Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 38(1): 7-9 (2024). https://doi.org/10.61873/OEFM7580. The publisher will update the PDF and HTML versions of the paper on the journal’s website, and will alert downstream indexes and databases through supplying updated metadata.

Citation

Please cite as:

Iatrakis G., Zervoudis S., Sarella A.,Tsikouras P., Paschopoulos M., Balafouta M., Peitsidis P. Should ultrasound assessment of the endometrium be necessary in patients treated with Tamoxifen? Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 38 (1): 7-9 (2024). https://doi.org/10.61873/OEFM7580